| A Message from BioStem Technologies Inc.
| IS BSEM ABOUT TO OUTGROW THE OTC? PROFITABLE EXECUTION, BREAKTHROUGH CLINICAL DATA, AND A $25.50 ANALYST TARGET SUGGEST A MAJOR RE-RATE COULD BE COMING! | | BioStem Technologies (BSEM) continues to separate itself from the noise in MedTech by delivering real earnings power.
In Q3 2025, the company reported $2.7 million in adjusted EBITDA—its seventh straight profitable quarter—while maintaining strong margins and a solid cash position.
Even with pricing pressure across the wound-care industry, BSEM's vertically integrated, GMP-compliant platform has allowed it to grow volume, protect profitability, and invest in long-term expansion.
The real potential upside lies in BioStem's clinical and market momentum. BioREtain® allografts have demonstrated superior wound-closure outcomes in peer-reviewed trials, targeting a global wound-care market measured in the tens of billions.
With new access points through federal programs, state Medicaid, and hospitals—and a planned Nasdaq uplisting in 2026—BSEM is building the foundation for institutional adoption and accelerated growth.
Analysts are already taking notice with a $25.50 price target that implies meaningful upside from current levels.
Discover why BSEM is emerging as one of the most compelling profitable MedTech stories in 2026 |
|
0 التعليقات:
إرسال تعليق